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Abstract
Autologous and allogeneic hematopoietic stem cell transplantation (HSCT) is the treatment of choice for patients with some
malignant and non-malignant hematological diseases. Advances in transplantation techniques and supportive care measures have
substantially increased the number of long-term HSCT survivors. This has led to an increasing patient population suffering from
the late effects of HSCT, of which, bone loss and its consequent fragility fractures lead to substantial morbidity. Altered bone
health, with consequent fragility fractures, and chronic graft-versus-host disease (GVHD) are factors affecting long-term quality
of life after HSCT. Hypogonadism, HSCT preparative regimens, nutritional factors, and glucocorticoids all contribute to accel-
erated bone loss and increased fracture risk. Management strategies should include bone mineral density examination, evaluation
of clinical risk factors, and general dietary and physical activity measures. Evidence has accumulated permitting recommenda-
tions for more attentiveness to evaluation and monitoring of bone health, with appropriate application of osteoporosis pharma-
cotherapies to patients at increased risk of bone loss and fracture.
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Introduction
Autologous or allogeneic hematopoietic stem cell transplanta-
tion (HSCT) is the treatment of choice for patients with some
malignant and non-malignant hematological diseases. HSCT
has substantially increased the number of long-term survivors
of hematologic malignancies, secondary to advances in trans-
plantation techniques and supportive care measures. As a con-
sequence, early and late complications of HSCT have
achieved greater importance. Bone loss and its clinical
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manifestation of fragility fractures is an important long-term
complication leading to substantial morbidity [1].
HSCT-related bone loss is multifactorial and incompletely
understood, occurring through a complex interaction of pre-,
peri-, and post-HSCT factors [2]. The complex interplay of cy-
tokines belonging to the tumor necrosis factor (TNF) superfam-
ily, the receptor activator of nuclear factor-kappa B ligand
(RANKL), and osteoprotegerin (OPG) [3] leads to an imbalance
between bone formation and resorption with resulting bone loss
[4] before and after the HSCT procedure. Risk factors may be
physiologic (aging, menopause in women, decline in androgen
levels in men) or be related to HSCT preparative regimens or
graft-versus-host disease (GVHD) prevention and treatment
(Table 1) [14]. For example, glucocorticoids are the best exam-
ple of drug-induced perturbation of the RANKL/OPG pathway
promoting bone loss [9]. Glucocorticoids can both increase bone
resorption and decrease bone formation in a dose- and duration-
dependent manner. Factors other than glucocorticoid use can
promote bone loss post-HSCT, including hypogonadism (sec-
ondary to chemotherapy and total body irradiation), secondary
hyperparathyroidism due to poor calcium and vitamin D nutri-
tion, and the effects of chemotherapy-induced toxicity to bone
cells and, importantly, bone marrow stromal cells.
Epidemiology of osteoporosis and fracture
in adult patients undergoing HSCT
Adult HSCT recipients generally are younger than patients
with postmenopausal osteoporosis, usually with a relatively
short pre-existing illness [15]. Overall, the prevalence of oste-
oporosis and osteopenia is relatively low at 4% and 24%,
respectively, when measured after chemotherapy, but prior to
HSCT [16]. The prevalence of osteopenia in adults with
HSCT is close to 50% after 4–6 years; that of osteoporosis
approaches 20% by 2 years after HSCT [17]. In studies of
long-term allogeneic HSCT, a large portion (52%) of HSCT
survivors has osteopenia at the femoral neck [18–20]. More
than 50% of patients undergoing allogeneic or autologous
HSCT suffer bone loss over the long term [11]. Variable bone
loss, often rapid, may occur at the proximal femur, less at the
spine, in the first 12 months, particularly after allogeneic
HSCT [15, 21, 22]. At 1 year after allogeneic HSCT, lumbar
spine bone mineral density (BMD) decreased by 4.8%, and
total proximal femoral BMD decreased by 12.3%. The lumbar
spine bone decrease was correlated to increased serum IL-6
and TNFα by 3 weeks after HSCT [23]. The decline in spine
BMD is associated with the cumulative glucocorticoid and
cyclosporine dose. Patients with acute GVHD ≥ grade II had
greater spine bone loss than patients with GVHD ≦ grade I
[23]. In contrast, after autologous HSCT, although femoral
neck bone loss is less (4%), it is not recovered after 2 years,
while spine BMD returns to baseline [24]. In a prospective
series of 180 autologous HSCT patients followed for a median
of 5.4 years and compared with 20 patients who received only
chemotherapy, the BMDdecrease was greater in older patients
but was also seen in younger patients: 35% of patients aged
25–35 years and 77% of those aged over 55 years had T-scores
of < -1. Bone loss was greatest in the first year after autolo-
gous HSCT, with the incidence of osteopenia/osteoporosis
reaching 65% in the HSCT population vs. 5% in the control
population. Some recovery was noted for spine and radius
BMD beginning 2 years after autologous HSCTwith mainte-
nance of BMD thereafter [5]. Autologous HSCT differs from
allogeneic HSCT in that GVHD does not occur and long-term
glucocorticoid use is much less frequent [25].
Fracture risk is increased after HSCT. A large retrospective
study of 7620 patients undergoing HSCTover 15 years showed
8% (602 patients) sustained fractures. Risk factors for fracture
included age older than 50 years, multiple myeloma, a solid
tumor, or an allogeneic HSCT. The relative risk was increased
eightfold and seven- to ninefold, in women and men, respec-
tively, compared with 45- to 64-year-old individuals from two
population-based cohorts [26, 27]. A substantial number of
patients with multiple myeloma, who are known to be a risk
of fracture independently of transplant, were included in this
study [28]. The risk was higher in allogeneic than in autologous
HSCT [27]. In another retrospective cohort study of 4160 con-
trol cancer patients and 1040 cancer patients who underwent
HSCT, the risk of fracture was 1.4 times higher in the HSCT
group compared to the non-HSCT group. Vertebral fracture
was the most common fracture site in the HSCT group
(68.4% of fractures) [29]. Other studies suggest that fracture
risk may not be increased after an allogeneic HSCT; however,
the cohorts were small and under-powered and the non-capture
of asymptomatic fractures could not be ruled out [30].
Multiple myeloma presents its own unique concerns, both
from the lytic bone lesions and from generalized bone loss
related to the disease and its treatment. Generalized bone loss
can result from cytokine activation of osteoclasts with de-
creased osteoblastic activity. Chemotherapy and autologous
stem cell transplantation are common treatment modalities; less
often allogeneic HSCT is utilized. Intravenous bisphosphonates
are of clinical benefit in the treatment of bone disease in pa-
tients with multiple myeloma, first reported with pamidronate
infusions where there were benefits to hypercalcemia, pain,
quality of life, fractures, and overall survival [31]. Zoledronic
acid was demonstrated more effective than pamidronate and
recently, monthly denosumab injections have been shown to
give similar benefits to zoledronic acid infusions [32].
Immunological factors
The interaction between hematopoietic bone marrow cells and
bone cells has become a subject of intense interest in recent
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years, referred to as osteoimmunology [33, 34]. A cross-talk
between the immune system and bone is well recognized with
systemic and local bone loss as a consistent consequence of
infection, inflammation, and autoimmune disorders [35].
Osteoclast differentiation is facilitated by bone marrow
stromal cells, which provide physical support for nascent os-
teoclasts and produce soluble and membrane-associated
growth factors [36]. Two necessary cytokines required for
osteoclast formation are RANKL and macrophage colony-
stimulating factor (M-CSF), which are primarily produced
by bone marrow stromal cells, osteoblasts, and activated T
cells [37]. RANKL is a TNF superfamily member, which
exists in membrane-bound and soluble forms. It is produced
by osteoblasts and binds to the transmembrane RANK recep-
tor on osteoclasts and osteoclast precursors. Osteoprotegerin
(OPG), secreted by osteoblasts and numerous hematopoietic
cells, acts as a decoy receptor for RANKL and thereby inhibits
osteoclast activation. The balance between RANKL and OPG
controls bone remodeling [37].
Other cytokines are responsible for the upregulation of os-
teoclast formation in several pathologic conditions such as
inflammation, cancer, and estrogen deficiency. The most im-
portant one is TNFα, which upregulates the stromal cells pro-
duction of RANKL andM-CSF [38] and increases the respon-
siveness of osteoclast precursors to RANKL [39]. TNFα not
only increases osteoclast formation and stimulates osteoclast
activity [40] through a direct action independent of RANKL
[41], but also inhibits the osteoblastogenesis, by blocking the
differentiation of new osteoblasts from their progenitors and
suppressing mature osteoblast function [42].
Among other cytokines, IL-1 promotes RANKL expres-
sion by bone marrow stromal cells and osteoblasts and stim-
ulates osteoclast lifespan and activity [43]. IL-7 is a powerful
lymphopoietic cytokine that may induce bone loss by T cell-
and B cell-mediated mechanisms [44]. Initially described as
an anti-osteoclastogenic cytokine (because of its power to in-
hibit osteoclastogenesis in vitro) [45], IFNγ promotes bone
resorption and causes bone loss in disease experimental
models and in several conditions in humans [46]. IL-23 has
recently been linked to inhibition of osteoclast formation, by
presumably inhibiting the activity of osteoclastogenic Th17
lymphocytes [47]. In patients with autologous or allogeneic
HSCT, bone turnover markers and inflammatory cytokines are
increased [23]. The closer the proximity of chemotherapy to
HSCT is, the greater the magnitude of bone loss at the hip
[48].
Recently, genetic variants (SNP) have been associated with
accelerated declines in bone density after HSCT [49]. Sixteen
SNPs were associated with spine or femoral BMD loss, three
of which have been previously implicated in genome-wide
association studies of bone phenotypes (COL1A1, RANKL,
and ESR1).
Osteoimmunology also encompasses the relationship be-
tween mesenchymal stem cell systemic infusion and its effect
on bone cells and GVHD. Early reports suggest a beneficial
effect of mesenchymal stem cell infusion on GVHD, possibly
leading to less need for glucocorticoid therapy and potentially
less bone loss [50]. Some preclinical studies have shown that
allogeneic mesenchymal cell therapy promotes osteoblasto-
genesis and prevents glucocorticoid-induced osteoporosis
[51]. Clinical trials of MSC therapies that involve different
diseases and conditions such as osteoporosis and GVHD are
ongoing. Due to the immunomodulation and immunosuppres-
sive properties of MSCs, MSC infusion may play a role in
bone health in the future [52].
Features promoting bone loss in HSCT
patients
Over the last 10 years, survivorship of patients undergoing
HSCT has improved due to advances in supportive care and
HSCT techniques. This has led to an enlarging and older pa-
tient population more likely to experience the late effects of
HSCT, of which, bone loss and fractures lead to substantial
morbidity.
Bone metabolic changes
The pattern and type of bone disease following HSCT differs
from other forms of osteoporosis occurring after transplanta-
tion of solid organs, due to the younger age of recipients and
the possible effect of the underlying hematologic disease and
its treatment [15, 17]. Reports on HSCT and bone loss incor-
porate various hematologic disorders and to date, there are no
reports that distinguish the risk of bone loss according to the
underlying hematologic disease.
Bone loss occurs at all skeletal sites, but is greatest at the
proximal femur [53]. It takes place during the first 3 to
12 months after HSCT, with marked declines in bone density
especially at femoral site detected within the first 100 days
post-allogeneic HSCT [22, 54]. Thereafter, a slow and incom-
plete recovery of bone density may take place at the femur
Table 1 Risk factors for bone loss pre- and post-stem cell
transplantation
Pre-HSCT risk factors Post-HSCT risk factors
Advanced age [5] Graft-versus-host disease [6]
Female sex [5] Calcium and vitamin D insufficiency
leading to secondary hyperparathyroidism [7]
Chemotherapy [8] Glucocorticoids [9]
Hypogonadism [10] Renal dysfunction [11]
G-CSF treatment [12]
Renal wasting of calcium or magnesium [13]
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over months to years, depending on patients’ other risk factors
and therapies [55].
A two- to threefold reduction in progenitor cells in the bone
marrow of auto- and allo-HSCT recipients compared to nor-
mal donors is observed after HSCT and may contribute to the
mechanism of bone loss [56]. A marked and permanent quan-
titative and qualitative defect in marrow osteogenic cells has
been reported, suggesting that inability to store a normal num-
ber of osteoblast precursors in the bone microenvironment
may account at least in part for severe bone loss after both
auto- and allo-HSCT [14]. The reduced repopulating capacity
of osteoblast precursors is a multifactorial process likely relat-
ed to effects of chemotherapy/radiotherapy, endocrine disor-
ders, immunosuppressive therapies, and altered balance of
cytokines and growth factors.
In some solid tumors, multiple myeloma, and certain types
of lymphoma, there is a propensity for spread and growth in
the bone through the formation of osteolytic bone lesions [57,
58]. These tumors produce cytokines, which enlist normal
host osteoclasts to resorb bone. Granulocyte colony-
stimulating factor (G-CSF) is secreted by osteoblasts and
stimulates osteoclastogenesis in vivo and in vitro, but at a
much lower rate than other colony-stimulating factors (M-
CSF and GM-CSF). G-CSF support after high-dose chemo-
therapy and G-CSF hematopoietic cell mobilization are often
part of standard HSCT therapeutic regimens, and its adminis-
tration not only mobilizes granulocytes, but also increases the
numbers of osteoclast precursors and osteoclasts. Short-term
G-CSF thus induces osteoclastic bone resorption and may be a
factor in the pathogenesis of osteoporosis following HSCT
[12].
Kidney-liver dysfunction, vitamin D,
and hypogonadism
Recipients of allo-HSCT may experience renal dysfunction
and altered vitamin D metabolism, in various degrees
resulting from HSCT and its related therapies (cyclosporine,
amphotericin). Non-malignant late effects of HSCT on liver
function can be seen including chronic GVHD or conse-
quences of iron overload. Altered kidney and liver function
as well as gastrointestinal symptoms lead to a reduced intake
and altered metabolism of calcium and vitamin D, sometimes
resulting in secondary hyperparathyroidism and increased os-
teoclastic bone resorption [11].
There can be reduced serum levels of 25-hydroxyvitamin
D3 in the course of allo-HSCT by reduced sun exposure and
vitamin D-deficient diets [11, 14]. A decline in estrogen in
women and testosterone in men is associated with bone loss
[59]. This is relevant as premature ovarian failure and
hypogonadism are the most common long-term endocrine ef-
fects affecting young patients after HSCT. Ovarian failure
occurs in 70–95% of young women after HSCT [60–62].
Secondary ovarian insufficiency in premenopausal women
who receive chemotherapy or whole body irradiation is well
established, with less than 30% recovering post-transplant
[10, 55].
Role of glucocorticoids and calcineurin inhibitors
In most series, bone loss is more severe and occurs over a
longer time frame after allo-HSCT than after auto-HSCT [24,
55]. Both transplant types are preceded by a similar intensity of
conditioning. The main differences between these two ap-
proaches are related to the involvement of the immune system,
as allo-HSCT is associated with a greater cytokine release, the
possibility of GVHD, and the use of immunosuppressive treat-
ments, all of which will predispose to greater bone loss [6, 63].
The use of chronic high-dose glucocorticoids is known to
increase the risk of osteoporosis-related fractures [9]. The
principal mechanisms responsible for induced bone loss are
as follows: an increased apoptosis of osteoblasts and osteo-
cytes; inhibition of osteoblast bone formation (reduced ex-
pression of TGF-β and inhibition of BMP2 and IGF-1 ef-
fects); decreased proliferation and differentiation of periosteal
precursor cells.
Chemotherapy regimens used in most lymphoid malignan-
cies include short courses of glucocorticoids. By contrast, the
onset of GVHD in the post-transplant setting is the main rea-
son for high-dose and prolonged glucocorticoid therapy.
Many studies in long-term HSCT survivors have confirmed
the correlation between bone loss and the use of glucocorti-
coids; patients on high-dose long-term glucocorticoids are
candidates for early introduction of preventive measures, to
maintain bone health [64].
Calcineurin inhibitors such as cyclosporine (CSP) and tacro-
limus (FK506) contribute to bone loss associated with trans-
plantation. Since glucocorticoids are usually co-prescribed with
CSP, it has been difficult to define its contribution to clinical
bone loss [14, 55]. CSP-induced bone loss occurs mainly at
sites rich in cortical bone and is related to dose and duration
of exposure. The exact mechanism of CSP’s effects on osteo-
blasts and osteoclasts is still unclear. CSP induces higher bone
turnover independent of renal function, decreases osteoblast
proliferation, and decreases magnesium stores, important for
vitamin D hydroxylation [65]. Recently, systemic lupus pa-
tients treated with CSP alone were found to have increases of
FGF 23, which correlated with CSP cumulative dose, possibly
etiologic in bone loss [66]. It remains debatable whether
GVHD itself or its treatment in the form of glucocorticoid or
cyclosporine has the greatest impact on bone health.
Radiotherapy and chemotherapy
Radiotherapy to bone has been associated with osteoporosis
and increased bone fragility [67]. There is some evidence that
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pelvic radiation reduces BMD by 11% at the femoral neck at
6 months in a prospective longitudinal study [68]. A full un-
derstanding of the pathophysiology underlying the radiation-
induced bone loss is still missing, but cell cultures and pre-
clinical studies have shown that irradiation increases osteo-
blast apoptosis and reduces osteoblast number, indicating that
a decrease in bone formation may be an important contributor
to bone loss [69]. Direct bone damage is mediated by in-
creased osteoclast activity leading to increased bone resorp-
tion and porosity. There are also some data indicating that
radiation can cause damage to bone matrix and the vascular
supply to bone.
Patients receiving standard dose chemotherapy for hema-
tological malignancies may be at risk of bone loss due to direct
effects on osteoblasts. Some chemotherapy regimens (metho-
trexate, cyclophosphamide, and cisplatin) have a direct toxic
effect on bone cell function [11, 14]. Methotrexate (MTX)-
induced osteopenia has been widely studied in patients with
rheumatoid arthritis; MTX has been shown to inhibit osteo-
blast proliferation and activity and stimulates osteoclast re-
cruitment [70]. High-dose cyclophosphamide may induce
nephrotoxicity and hypophosphatemia, also associated with
decreased osteoblast activity [8, 71]. Cisplatin induces hypo-
magnesemia (causing decreases in 25-hydroxyvitamin D) and
hypocalcemia (leading to increased parathyroid hormone
(PTH) levels).
Role of conditioning
In most studies on long-term bone complications in HSCT,
conventional myeloablative conditioning regimens were ap-
plied [72, 73]. Over the last 10 years, non-myeloablative or
reduced intensity regimens (RIC) for HSCT have become
more common, reducing treatment-related mortality and mor-
bidity [74]. RIC-HSCT regimens are frequently used in older
patients. There are no studies addressing whether less inten-
sive chemotherapy will be less harmful to bone. However, this
might be counterbalanced by the older age of recipients and
the higher incidence of GVHD with consequent immunosup-
pressive treatments in RIC-HSCT [74].
Lifestyle habits and comorbidities associated
with bone loss
There are numerous comorbidities and adverse lifestyle habits
associated with bone loss and fracture in postmenopausal os-
teoporosis, many of which are FRAX risk factors. There are
no published reports of the interaction of FRAX risk factors
with the added risks of HSCT, though it might be assumed that
risks such as smoking, alcohol, prevalent fracture, and rheu-
matoid arthritis might be additive in these patients.
Bone marrow imaging: current method
and recent advances
Most malignant hematological disorders are associated with
bone marrow (BM) infiltration. Magnetic resonance imaging
(MRI) is a non-invasive method to assess the nature and con-
tent of BM, although the gold standard for evaluating BM
infiltration is bone marrow biopsy [75]. T1-weighted se-
quences provide optimal differentiation between normal and
pathological tissues (which have a high signal), allowing eval-
uation of the cellular content of BM, where the intensity of
signal is directly proportional to the amount of fat in BM. T2-
weighted sequences with fat suppression or STIR (short T1
inversion recovery) show a high signal in regions of high
cellularity [76].
Immediately after HSCT, BM displays a low signal on T1-
weighted sequences and a high signal on T2-weighted images,
suggesting peri-treatment edema. After around 3 months, BM
appears as a characteristic Btarget image^with a hyper-intense
zone (at the region rich in fat) surrounded by a hypo-intense
halo in T1-weighed sequences, representing the hematopoietic
repopulation of the bone. Later, this signal difference disap-
pears, and a year after allo-HSCT, the image becomes more
homogeneous with conversion into fatty marrow. Such BM
changes are likely reflective of a good recovery of BM
function.
There are a number of MRI artifacts after HSCT.
Allogeneic transplants may display a high signal on T1-
weighted sequences. However, the type of HSCT, autologous
or allogeneic, does not affect the MRI image [77].
P o s i t r o n em i s s i o n t o m o g r a p h y w i t h 1 8 -
fluorodeoxyglucose (18-FDG) integrated with computed to-
mography (PET-CT) evaluates metabolic functioning of tis-
sues. PET-CTcan estimate the extramedullary extent of hema-
tological disease. Resolution of areas of tracer accumulation
after HSCT is an indicator of survival [78].
Published guidelines for HSCT management
Guidelines for screening and prevention of bone loss for long-
termHSCTsurvivors were published in 2006 by the European
Group for Blood and Marrow Transplantation (EBMT),
Center for International Blood and Marrow Transplant
Research (CIBMTR), and the American Society for Blood
and Marrow Transplantation (ASBMT) [79]. The recommen-
dations were reviewed and updated in 2012 by an internation-
al group of experts including members from EBMT,
CIBMTR, ASBMT and Asia-Pacific Blood and Marrow
Transplantation Group, Bone Marrow Transplant Society of
Australia and New-Zealand, East Mediterranean Blood and
Marrow Transplantation Group, and Sociedade Brasileira de
Transplantante de Medula Ossea [80]. As rapid bone loss
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usually takes place 3–12 months post-transplantation, guide-
lines recommend dual X-ray absorptiometry (DXA) at 1 year
after transplantation and at an earlier time point for patients
with GVHD and prolonged glucocorticoids and/or calcineurin
inhibitor exposure. All HSCT patients should also receive
dietary and lifestyle advice, including calcium and vitamin
D supplementation, physical activity, and fall prevention.
Sex hormone therapy should be considered in menopausal
women and in hypogonadal men. Bisphosphonate therapy
should be considered in patients with osteoporosis or who
are at high risk of bone loss and/or fracture.
Evaluation of patients pre-/post-HSCT
Despite a lower fracture risk in autologous than in allogeneic
HSCT, the following guidances concern both types of HSCT,
taking into account however that most of the therapeutic trials
have been conducted in the latter.
Bone mineral density assessment
Dual-energy X-ray absorptiometry (DXA) is a measurement
of areal BMD, used to diagnose osteoporosis on the basis of
the T-score (T-score − 2.5 and below), comparing a patient’s
BMD with normative data from young women at peak bone
mass. For children and adults aged < 50 years, Z-score (which
is the comparison of the measured BMD with the mean BMD
of an age-/gender-matched population) is the preferred meth-
od of reporting BMD [81]. Accepted sites for the diagnosis of
osteoporosis include the femoral neck, total hip and spine
(one-third radius, if hip or spine sites are not valid); the lowest
score is used for diagnosis. The risk of fracture in older adults
increases roughly twofold for each SD decrease in BMD [82].
FRAX®
Integrating clinical risk factors with BMD in assessing
fracture risk [83], FRAX is an evidence-based calcula-
tion of a patient’s 10-year probability of major osteopo-
rotic fracture (spine, hip, forearm, and proximal humer-
us) and hip fracture. FRAX utilizes age, sex, body mass
index, personal and family history of fracture, smoking,
alcohol intake, chronic glucocorticoid use, rheumatoid
arthritis, other causes of secondary osteoporosis, and
femoral neck BMD. FRAX is widely used in the non-
transplant setting to evaluate the need for therapy for
osteoporosis. A recent retrospective review of FRAX
for the prediction of fracture after HSCT showed that
FRAX had a modest ability to predict osteoporotic frac-
ture [84].
Bone turnover markers
Bone turnover is the principal factor influencing both the qual-
ity and the quantity of bone in the adult skeleton. High bone
turnover in postmenopausal women leads to bone loss and
altered bone microarchitecture. Bone turnover can be assessed
indirectly by measuring biochemical bone turnover markers,
categorized as bone formation markers (osteocalcin (OC),
bone alkaline phosphatase (BAP), type 1 procollagen-N
propeptide (P1NP)) and bone resorption markers
(deoxypyridinoline (DPD), type 1 collagen cross-linked N-
telopeptide (NTX), type 1 collagen cross-linked C-telopeptide
(CTX), tartrate-resistant acid phosphatase 5b (TRAP 5b)), ei-
ther in blood or urine. Bone turnover markers are an indepen-
dent predictor of fracture risk, synergistic with BMD, but can-
not be used to diagnose osteoporosis [85]. Bone turnover
markers may be a useful tool to assess drug efficacy; serum
CTX is markedly suppressed by antiresorptive therapy and
serum P1NP shows an early and substantial increase to bone
anabolic therapy with teriparatide [86]. CTX and P1NP are the
preferred resorption and formation markers recommended to
be used in all clinical trials [87]. However, the value of bone
turnover markers in clinical practice is limited by intra- and
inter-assay variability.
Vitamin D
Vitamin D deficiency is common in allo-HSCT patients [88].
This may be the result of decreased sunlight exposure from
prolonged hospital stays, isolation, and low outdoor physical
activity during chemotherapy. Gastrointestinal GVHD after
HSCT may further limit absorption of vitamin D. Some medi-
cations such as calcineurin inhibitors, amphotericin, and gluco-
corticoids used inHSCT patients, as well as accompanying renal
insufficiency, can interfere with vitamin D metabolism, leading
to vitamin D insufficiency or impaired conversion of vitamin D
to active metabolite vitamin D. In a retrospective study at MD
Anderson Hospital (Houston, USA), Joseph et al. found that the
median vitamin D level in patients undergoing transplantation
was 16 ng/mL (40 nmol/L), with 70% of patients being vitamin
D-insufficient [7]. Similarly, Urbain et al. [89] recently reported
that in a cohort of allo-HSCT patients, 25-hydroxyvitamin D
concentrations were 16.4 ± 8.9 ng/mL (41 nmol/L), with 89%
of patients having insufficient levels. Moreover, vitamin D de-
ficiency before HSCT was associated with an increased risk of
GVHD [90]; vitamin D is known to play a role in the differen-
tiation process of hematopoietic precursor cells [11].
Strategy
All candidates should be evaluated with DXA hip and spine as
soon as HSCT has been planned. In older individuals or pa-
tients at risk, spine X-rays or vertebral fracture assessment by
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DXA (VFA) should be performed to identify vertebral frac-
tures. FRAX most likely underestimates fracture risk in this
population. An evaluation of the common modifiable risk fac-
tors of osteoporosis and fractures should be undertaken. These
include hyperparathyroidism, hypogonadism, smoking, use of
loop diuretics and low intake of dietary calcium and protein,
and vitamin D insufficiency [22]. Individuals with osteoporo-
sis who are awaiting HSCT should be evaluated and treated
similarly to others with osteoporosis. Follow-up DXA is rec-
ommended as early as 3 months post-HSCT in patients at high
risk; lower risk patients may be followed with DXA at annual
intervals. Screening intervals may be reduced or extended
based on BMD measurement and the presence or absence of
other risk factors (e.g., age, gender, low body weight,
hypogonadism, time since transplantation, ongoing use of
glucocorticoids).
Treatments considerations
Vitamin D and calcium
Calcium supplementation alone is not effective in preventing
bone loss after HSCT [91]; however, an adequate intake of
calcium (800–1200 mg/day) via dietary sources and/or sup-
plements should be recommended. Vitamin D supplementa-
tion (at least 800 IU/day) is also recommended as vitamin D
deficiency has a high prevalence and may contribute to low
bone mass in patients after HSCT [92, 93]. In addition, the
efficacy of osteoporosis medications has predominantly been
demonstrated in the presence of vitamin D and calcium sup-
plementation [94]. Therapy should achieve serum 25-
hydroxyvitamin D levels of > 30 ng/mL (75 nmol per liter)
[93]. An increase in cardiovascular risk in patients taking cal-
cium supplements has not been validated in a recent meta-
analysis of older individuals; cardiovascular risk related to
calcium supplements has not been shown in HSCT patients
[95]. Other non-pharmacological measures include regular
weight-bearing physical activity, smoking cessation, and mea-
sures to prevent falls; efficacy of these measures has also not
been assessed in HSCT patients.
Bisphosphonates
Bisphosphonates are the drugs that have beenmost often stud-
ied to prevent HSCT-induced bone loss. Therapeutic regimens
varied widely and most of these studies include small and
often heterogeneous populations and did not consider the T-
score before therapy or other risk factors for fracture. Only
seven randomized trials of antiresorptive therapy have been
published (Table 2). The control group most often received
calcium and vitamin D supplements alone. One study evalu-
ated two different bisphosphonates [97]. Oral risedronate was
used in two studies [54, 97], pamidronate in two [96, 98], and
zoledronic acid in four [97, 99, 101, 102]. With the exception
of the risedronate study, more intensive schedules than the
ones shown to be effective for the treatment of postmenopaus-
al osteoporosis have been used [103].
The majority of patients were enrolled in trials evaluating
pamidronate. Kananen et al. randomized 99 patients prior to
HSCT with or without 60 mg pamidronate infusions before
and 1, 2, 3, 6, and 9 months after HSCT [96]. Lumbar spine
BMD remained stable in the pamidronate group, but despite
the relatively high doses of pamidronate, BMD still decreased
at the femoral neck and total hip. Using even higher doses of
pamidronate, comparable to the ones used for the treatment of
bone metastases [104], Grigg et al. reported similar findings
[98]. They randomized 116 patients to receive calcitriol and
calcium with or without monthly 90 mg pamidronate infu-
sions for 1 year. Pamidronate prevented BMD loss at the lum-
bar spine but BMD still declined at femoral neck and total hip,
although the decrease was significantly less in the
pamidronate group than in the control group. One year after
therapy, only the BMD benefit at the total hip remained sig-
nificant between the two groups. The infusion of three month-
ly doses of zoledronic acid (4 mg) after allogeneic HSCT
increased both lumbar spine and femoral neck BMD at
12 months compared to pre-treatment BMD [97, 102].
In summary, bisphosphonates generally prevented bone
loss [98, 101] or increased bone mass [97, 102]. A meta-
analysis confirmed that bisphosphonates, and in particular,
zoledronic acid, are promising in the prevention of HSCT-
induced bone loss [28].
Although these studies have shown that bisphosphonates
are well tolerated and can prevent or mitigate bone loss after
HSCT, available data are insufficient to demonstrate the supe-
riority of a specific agent or dosing schedule over another. The
majority of studies have treated patients for 12 months but the
optimal duration of therapy is unknown. Grigg et al. have
shown persistence of bone loss after discontinuation of
pamidronate [98]. Fracture data are not available in any of
the studies.
Prophylactic treatment with bisphosphonates regardless of
baseline T-score should be strongly considered, especially in
patients receiving glucocorticoids for GVHD after HSCT,
since these patients are at even higher risk for bone loss.
Stern et al. showed that spine BMD did not predict fracture
risk and, like glucocorticoid-induced osteoporosis, fractures
may occur in patients with only slightly reduced T-scores
[53]. Furthermore, the onset of bone loss may be rapid, occur-
ring within the first months after HSCT.
Long-term bisphosphonate treatment may be associated
with serious bone adverse effects with a very low incidence.
Osteonecrosis of the jaw (ONJ) is defined as a bone exposure
within the buccal cavity lasting for more than 8 weeks, which
may occur more frequently after a tooth extraction or oral
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surgery. The frequency associated with high-dose
bisphosphonates for bony metastatic disease is estimated be-
tween 1 and 5% [105], but there are no data specific to HSCT
patients. A recent review and international consensus of ONJ
in patients on osteoporosis doses of bisphosphonate reported
the frequency to be between 1 and 90 per 100,000 patient
years [106]. There are no data concerning bisphosphonate-
associated atypical femoral fractures in this population.
Menopausal hormone therapy
Estrogen-/progesterone-based menopausal hormone therapy
(MHT) is generally recommended in patients with premature
ovarian failure to prevent diseases associated with estrogen
loss [107]. Possible complications associated with MHT in
postmenopausal women, such as an increased risk of throm-
boembolism, stroke, and breast cancer, are not applicable in
women before age 45 years.
A lesser decline in BMD in young female patients receiv-
ing MHT in comparison with patients without MHT has been
reported [97]. However, MHT has not been consistently
shown to prevent BMD loss after HSCT [64, 96]. Therefore,
MHT alone may constitute insufficient treatment for the mul-
tifactorial bone loss in patients after HSCT.
Selective estrogen receptor modulators
The selective estrogen receptor modulator raloxifene is an
antiresorptive therapy reducing postmenopausal bone loss,
preventing vertebral fractures, and with reductions in breast
cancer incidence; there are no data in HSCT patients [108].
Denosumab
Denosumab, a fully human monoclonal antibody to RANKL,
is an effective antiresorptive therapy for osteoporosis, leading
to significant reductions in the risk for hip, vertebral, and non-
vertebral fractures in postmenopausal osteoporosis [109].
Denosumab could be quite promising in preventing bone loss
after HSCT because of its potent anti-osteoclastic activity, its
larger effect on cortical bone than bisphosphonates, and its
lack of renal toxicity [110]. Denosumab’s antiresorptive ef-
fects are more rapidly reversible on discontinuation of therapy
as compared with bisphosphonates; a long-term strategy is
therefore required [111]. A case report of a young woman on
dialysis after allo-HSCT for acute myeloid leukemia reported
improvements in BMD after treatment with denosumab [112].
Controlled clinical trials are required to evaluate the role of
denosumab in HSCT patients.
Parathyroid hormone-derived peptides
Teriparatide has been shown to have superior BMD effects
compared with bisphosphonate in glucocorticoid-induced os-
teoporosis [113]. PTH or PTHrP analogs (such as
abaloparatide) might be interesting alternatives to
antiresorptive therapy because of their stimulating effect on
bone formation. PTH or PTHrP analogs are, however,
Table 2 Randomized trials of therapies to prevent bone loss in HSCT patients: BMD results at 12 months post-transplant
Study author Intervention n BMD lumbar spine
(percent change)
BMD total hip
(percent change)
BMD femoral neck
(percent change)
Valimaki et al.
1999 [91]
Calcium/vitamin D versus intranasal calcitonin 12 − 4.1 − 8.2
12 − 4.1 − 8.2
Tauchmanovà
et al. 2003 [54]
Calcium/vitamin D versus risedronate 35 mg per
week
17 − 3.1 − 4.1 − 4.2
17 5.9 1.3 1.3
Kananen et al.
2005 [96]
Pamidronate 60 mg IV 0, 1, 2, 3, 6, 9 months plus
estrogen versus estrogen alone
50 – − 5.5 − 4.2
49 − 2.9 − 7.8 − 6.2
Tauchmanova
et al. 2006 [97]
Calcium/vitamin D versus estrogen versus
risedronate
versus zoledronic acid 4 mg monthly × 3
15 − 4.3 − 4.2
15 – –
15 5.8 –
10 8.6 5.4
Grigg et al. 2006
[98]
Pamidronate 90 mg IV monthly plus HRT plus
calcitriol
versus HRT plus calcitriol
63 2.1 − 3.1 − 2.3
53 − 2.6 − 8.2 − 11
Hari P et al. 2013
[99]
Calcium/vitamin D versus zoledronic acid 4 mg 0,
3,
and 6 months
29 − 5.0 − 6.0
32 4.2 2.0
Grigg A et al.
2017 [100]
Pre-transplant zoledronic acid 4 mg IV followed by
post-transplant zoledronic acid 4 mg IV
determined by a risk-adapted algorithm
70 − 2.9
HRT hormone replacement therapy
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contraindicated in patients with radiotherapy to the skeleton or
any malignant diseases of the skeleton, excluding HSCT pa-
tients from currently available bone anabolic therapy. There is
no experience with PTH or analogs in patients after HSCTand
it is unlikely that a therapeutic trial will ever be conducted.
Romosozumab, a sclerostin monoclonal antibody, releases
osteoblasts from inhibition by sclerostin with resultant in-
creases in BMD and fracture reduction in postmenopausal
women with osteoporosis. Regulatory approval of
romosozumab awaits confirmation of cardiovascular safety
and specific trials in the HSCT population will be required.
Algorithm for management of bone health
in allogeneic HSCT patients
Risk factors predicting bone loss
Risk factors for bone loss following HSCT are multifactorial
and include the HSCT preparative regimen, induction of pre-
mature menopause, weight loss, and medications used in the
prevention and treatment of acute and chronic GVHD.
Reduced intensity conditioning regimens are increasingly
used and are associated with less organ toxicity but it is un-
known if they are associated with a reduction in bone loss.
The integration of clinical risk factors with femoral neck
BMD has been operationalized into the FRAX 10-year frac-
ture risk probability. FRAX is not applicable in patients under
the age of 40 and has not been validated in the HSCT popu-
lation. Patients with GVHD typically are given high doses of
glucocorticoid and the dose of glucocorticoid is not included
in FRAX calculations.
Secondary causes of bone loss may coexist in this HSCT
population. For this reason, secondary causes of bone loss
should be evaluated with measurement of calcium, phosphate,
ALP, TSH, creatinine (estimated glomerular filtration rate
(eGFR)), and 25-hydroxyvitamin D (25-OHD). In some clin-
ical circumstances, PTH, morning testosterone, estradiol,
FSH, and LH could be measured (Fig. 1).
When to test BMD
Evaluation of BMD at hip and spine prior to HSCT is recom-
mended due to prior morbidity and exposure to chemotherapy
agents potentially harmful to bone. Most guidelines recom-
mend DXA within 1 year of transplant [73, 79, 117]. Post-
transplant declines in BMD are not predictable. For this rea-
son, BMD measurement should be repeated in patients not
given pre-transplant bone resorption inhibitors, 3 months after
HSCT (Fig. 1). If patients have been given zoledronic acid
pre-transplant, a repeat BMD 1 year after the treatment is
recommended. Individual patients with specific clinical con-
cerns may require follow-up evaluations at an earlier time
point. It should be noted that many studies of antiresorptive
therapy in this population use higher doses of bisphosphonate
than are indicated for postmenopausal osteoporosis. There are
data indicating that BMD may be low in patients many years
after HSCT. For this reason, BMD should be monitored peri-
odically in patients who have had HSCT in the past [55].
Diet and lifestyle recommendations
General good nutrition is required for optimal bone health.
Food intake and gastrointestinal (GI) absorption are reduced
after HSCT and may be more problematic with GI GVHD.
Because of frequent post-HSCT nutritional deficiency, atten-
tion to adequate caloric intake with the addition of total par-
enteral nutrition (TPN) if required early post-HSCT is
desirable.
Adequate intake of calcium, protein, and vitamin D is rec-
ommended [55]. Although dairy intake should be encouraged,
calcium supplements could be used to supplement patients’
need for 1000–1200 mg elemental calcium from diet and sup-
plement combined.
Baseline assessment of serum 25-hydroxyvitamin D may
help to determine patients in need of a loading dose of vitamin
D prior to transplant. A loading dose of vitamin D3 (for ex-
ample, 50,000 to 100,000 IU) prior to HSCT would aid in
ensuring vitamin D sufficiency throughout the critical first
3 months [118].
All patients should be educated about general exercise and
lifestyle interventions to reduce bone loss such as regular
weight-bearing and muscle-strengthening exercises and
avoidance of tobacco and excessive alcohol intake.
Intervention thresholds, factors influencing
intervention thresholds
Intervention with pharmacotherapy in HSCT patients should
be recommended earlier than in patients with postmenopausal
or idiopathic osteoporosis. We have previously recommended
earlier intervention at a higher BMD threshold for patients on
aromatase inhibitor or androgen deprivation therapy [119].
Intervention with intravenous zoledronic acid should be con-
sidered if pre-HSCT BMD T-score ≦ -1.5 at any one of the
relevant sites (total hip, femoral neck, lumbar spine) and if
renal status permits. Denosumab could be considered in pa-
tients with renal impairment, who are not candidates for bis-
phosphonate. Denosumab 60 mg twice yearly compared with
placebo effectively prevented clinical fractures in postmeno-
pausal women with breast cancer who received an aromatase
inhibitor, irrespective of baseline age or BMD [120].
Parenteral antiresorptive therapy is preferred due to the poten-
tial for poor absorption and adherence associated with oral
therapy [121], as well as GI side effects in this population
who are at particular risk (Fig. 1).
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All patients receiving prolonged courses of glucocorticoids
for GVHD are at high risk for bone loss and fracture. In addi-
tion, the duration of glucocorticoid therapy is often unpredict-
able. Therefore, prophylaxis with bisphosphonates, ideally zo-
ledronic acid 5 mg intravenously, may be given regardless of
the T-score. Additional risk factors such as prevalent fragility
fracture should be considered. Recent data demonstrate greater
effectiveness of denosumab in preventing glucocorticoid-
induced bone loss as compared with risedronate [122].
In younger women with treatment-induced amenorrhea
post-HSCT, estrogen-based MHT may prove to be an ef-
fective antiresorptive therapy and perhaps show additive
benefits with regard to cardiovascular disease [123], al-
though it does not prevent glucocorticoid-induced bone
loss in this population [96, 124].
Obstacles to implementation of bone health
guidelines for HSCT recipients
Despite convincing data that bone loss is common post-
HSCT, manyHSCT patients are not monitored for bone health
and the majority does not receive prophylactic intervention.
Pre-HSCT bone densitometry screening, using DXA, can
identify patients with pre-existing osteopenia/osteoporosis,
whomay benefit from early interventions to prevent or reverse
transplant-related bone loss. Given the high rates of early
transplant-related mortality and relapse, concerns have been
raised that such an approach may not be cost-effective [73].
The risk of renal dysfunction in patients receiving intrave-
nous zoledronic acid for osteoporosis is small. Transient in-
creases in serum creatinine are observed 9–11 days after
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Fig. 1 Management algorithm for
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algorithms created to aid
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glucocorticoid-induced osteopo-
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zoledronic acid infusion [125]. It is recommended that pa-
tients should be well-hydrated and not receiving agents that
are known to possibly adversely affect renal function [126].
Zoledronic acid dosing pre-transplant is best administered in
advance of HSCT conditioning and GVHD prophylaxis.
Challenges exist in administration in the early post-
transplant period due to the frequent use of calcineurin
inhibitors.
Denosumab is a promising agent for prevention of bone
loss in HSCT patients. Inhibiting the immunomodulatory ef-
fect of RANKL on both the innate and adaptive immune sys-
tems, denosumab theoretically could increase the risk of in-
fection and/or disease relapse in HSCT patients. If denosumab
had favorable immunomodulatory effects in these patients,
there might also be a reduction in GVHD; controlled clinical
trials are required.
Conclusions
HSCT procedures are increasing in frequency and HSCT pa-
tients are living longer leading to a focus on long-term out-
comes. Bone health comes to the fore as one of the most
significant morbidities post-HSCT.
Sufficient evidence has accumulated in HSCT patients to
make recommendations for more aggressive monitoring of
bone health and more appropriate application of osteoporosis
pharmacotherapies to patients at high risk of bone loss and
fracture.
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